Drugs

Article	Citations
Arimoclomol: First Approval	411
Iruplinalkib: First Approval	373
Empagliflozin: A Review in Symptomatic Chronic Heart Failure	283
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	265
Epcoritamab: First Approval	212
Tirzepatide: First Approval	189
Olutasidenib: First Approval	185
Pimitespib: First Approval	162
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	153
New Therapies on the Horizon for Primary Biliary Cholangitis	131
Tebentafusp: First Approval	127
Teprotumumab: A Review in Thyroid Eye Disease	116
Imetelstat: First Approval	112
Bone Fragility in Diabetes and its Management: A Narrative Review	103
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	99
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature	98
Mirvetuximab Soravtansine: First Approval	97
Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions	95
Vorasidenib: First Approval	94
Correction: Vorasidenib: First Approval	91
Vosoritide: First Approval	89
Aprocitentan: First Approval	89
Tunlametinib: First Approval	87
Crovalimab: First Approval	85
Zanidatamab: First Approval	85

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria	81
Etrasimod: First Approval	81
Difelikefalin: First Approval	81
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	80
Contemporary Management of Dyslipidemia	79
Avalglucosidase alfa: First Approval	79
Ocrelizumab: A Review in Multiple Sclerosis	79
Savolitinib: First Approval	77
Bexagliflozin: First Approval	76
Beremagene Geperpavec: First Approval	75
Correction: Iptacopan: First Approval	74
Dimdazenil: First Approval	74
Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles	72
Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals	72
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval	71
Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa	70
Correction to: Valemetostat Tosilate: First Approval	70
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	70
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting	69
Correction: Vonoprazan: A Review in Helicobacter pylori Infection	68
Correction to: Fostamatinib: A Review in Chronic Immune Thrombocytopenia	67
Zastaprazan: First Approval	67
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain	66
Correction to: Secukinumab: A Review in Psoriatic Arthritis	66
Correction to: Darinaparsin: First Approval	66
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice	65
Bimekizumab for the Treatment of Psoriasis	65
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	65
New Topical Therapies in Development for Atopic Dermatitis	63
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	63
Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review	63
Eye Involvement and Management in Inherited Epidermolysis Bullosa	62
The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis	62
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy	61
Spesolimab for the Treatment of Generalized Pustular Psoriasis	60
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	60
The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis	60
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	60
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	59
Targeting DNA Damage Response Deficiency in Thoracic Cancers	58
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	58
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	58
Comment on: “The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab”	57
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	57
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders	55
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	55
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	55
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	55
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	55
Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression	54

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	53
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations	53
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	53
Vamorolone: First Approval	52
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	52
Sulbactam/Durlobactam: First Approval	50
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	50
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	50
Zavegepant: First Approval	49
Ensifentrine: First Approval	48
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	48
Envafolimab: First Approval	48
Sotorasib: First Approval	47
Teclistamab: First Approval	47
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma	46
Mobocertinib: First Approval	46
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	46
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	45
Gastrointestinal Dysfunction in Parkinson’s Disease	45
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	45
Trofinetide: First Approval	45
Givosiran: A Review in Acute Hepatic Porphyria	44
Capivasertib: First Approval	44
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	43
Innovation in Targeted Intra-articular Therapies for Osteoarthritis	43
Xanomeline/Trospium Chloride: First Approval	43
Imeglimin Hydrochloride: First Approval	42
Current Medical Therapy for Adenomyosis: From Bench to Bedside	41
Tarlatamab: First Approval	41
Casirivimab/Imdevimab: First Approval	41
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	41
Iptacopan: First Approval	41
Eftrenonacog Alfa: A Review in Haemophilia B	41
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	41
Lotilaner Ophthalmic Solution 0.25%: First Approval	39
Update on the Treatment of Chronic Spontaneous Urticaria	39
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	39
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	39
Motixafortide: First Approval	38
Tremelimumab: First Approval	38
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight	37
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	37
Glofitamab: First Approval	37
Upacicalcet: First Approval	36
Tafolecimab: First Approval	36
Eladocagene Exuparvovec: First Approval	36
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	36
Ibrexafungerp: First Approval	36
Somatrogon: First Approval	36
Olipudase Alfa: First Approval	36
Cefepime/Enmetazobactam: First Approval	35
Correction to: Efanesoctocog Alfa: First Approval	34
Acknowledgement to Referees	34
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting	34
Evinacumab: First Approval	34
Interchangeability of Biosimilars: Overcoming the Final Hurdles	33
Correction to: Nadofaragene Firadenovec: First Approval	33
New Pharmacologic Approaches to the Treatment of Bipolar Depression	32
Avatrombopag: A Review in Thrombocytopenia	31
Drugs in Development to Manage Acute Pain	31
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature	31
Momelotinib: First Approval	30
Ivonescimab: First Approval	30
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	30
Maribavir: First Approval	30
Tegileridine: First Approval	30
The Future of Microbiome Therapeutics	29
Dasiglucagon: First Approval	29
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis	29
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	29
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma	29
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	28
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	28
Mavorixafor: First Approval	28
Melphalan Flufenamide (Melflufen): First Approval	27
Correction to: Eftrenonacog Alfa: A Review in Haemophilia B	27
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	27
Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome	26
Correction to: Maralixibat: First Approval	26
Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	26

Atogepant: First Approval	25
Danicopan: First Approval	25
Correction to: Efgartigimod: First Approval	25
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	25
Correction: Zilucoplan: First Approval	25
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	25
Linzagolix: First Approval	25
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders	24
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	24
Rozanolixizumab: First Approval	24
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	24
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients	24
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma	24
Authors’ Reply to Denning: Comment on: “Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries”	24
Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials	23
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis	23
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects	23
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	23
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	23
Drug-Induced Pigmentation: A Review	23
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future	23
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies	23
Results from Expanded Access Programs: A Review of Academic Literature	23
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	23
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity	23
Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”	22
On the Verge of Precision Medicine in Diabetes	22
Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now	22
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	22
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review	22
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	21
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	21
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	21
Correction: Estetrol/Drospirenone: A Review in Oral Contraception	21
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	21
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	21
Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics	21
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study	21
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs	20
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	20
Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature	20
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	20
Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials	20
Neuropathic Pain and Spinal Cord Injury: Management, Phenotypes, and Biomarkers	19
Tasurgratinib Succinate: First Approval	19
Repotrectinib: First Approval	19
Revumenib: First Approval	19
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	19
Correction to: Lenacapavir: First Approval	19
Concizumab: First Approval	19
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	19
Nogapendekin alfa Inbakicept: First Approval	19
Sovateltide: First Approval	18
Diagnosis and Treatment of AL Amyloidosis	18
Inavolisib: First Approval	18
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease	18
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer	18
Finerenone: First Approval	18
Drugs in Development to Treat IgA Nephropathy	18
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	18
Nemolizumab: First Approval	18
Androgenetic Alopecia: Therapy Update	17
Dostarlimab: First Approval	17
Deucravacitinib: First Approval	17
In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation	17
Lenacapavir: First Approval	17
Acute Pancreatitis: Diagnosis and Treatment	17
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	17
Donafenib: First Approval	17
Retifanlimab: First Approval	17
Tezepelumab: First Approval	17
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia	17
Zolbetuximab: First Approval	17
Contezolid: First Approval	16
Ravulizumab: A Review in Generalised Myasthenia Gravis	16
Keverprazan Hydrochloride: First Approval	16
Daridorexant: First Approval	16
Pirtobrutinib: First Approval	16
HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic	16
Olverembatinib: First Approval	16
Acknowledgement to Referees	16
Sutimlimab: First Approval	16
Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	15
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review	15
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms	15
Berdazimer Topical Gel, 10.3%: First Approval	15
Comment on: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	15
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	15
Drug Treatment of Cluster Headache	15
Pharmacological Management of Acute Endodontic Pain	15
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	15
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	15
Reply to Zhang and Zhu “MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19”	14
Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review	14
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care	14